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1. Rationale
Hepatic malignancies are one of the most challenging
presentations in oncology, not only because of their high
incidence but because of their recurrent nature and the
limited efﬁcacy of current treatments. With multiple
sequential lines of therapy, the risk of additive toxicities
increases overall, often with concurrent functional
changes to the liver.
External beam radiation therapy (EBRT) is the cor-
nerstone of curative and palliative therapy in many
malignancies, and is often used synergistically with
chemotherapy to improve outcome. However, until
recently, radiotherapy has not been applied with much
success to the liver due to the low tolerance of
liver parenchyma to doses above 35Gy. 1,2 This is
below the required dose of 45Gy or above (usually
with concurrent radio-sensitising chemotherapy) for
the radical treatment of microscopic disease from
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adenocarcinomas, particularly of rectal origin, and for
macroscopic disease such as liver metastases.
Seminal works by Withers (1988) 3 and Lawrence 4
have shown that complications do not occur unless the
threshold of liver damage exceeds the functional reserve.
Small portions of the liver can tolerate irradiation
well above 35Gy without signiﬁcant complications, as
long as sufﬁcient normal liver is spared from radical dose
radiation exposure. 4 These principles have been applied
successfully for stereotactic body radiation therapy of
small liver metastases 5,6 and also for selective internal
radiation therapy (SIRT) in the treatment of primary and
secondary liver tumours. 7
SIRT is a form of brachytherapy, which utilises the
high-density microvascularisation, 8 present in almost all
malignant tumours (greater than 5−10mm diameter), to
deliver high local doses of irradiation to liver tumours
via the hepatic arterial branches. 9 The concept of
SIRT was born in the 1950s, but its wider adoption
followed the development of the current generation of
products such as SIR-Spheres microspheres (yttrium-90
[90Y] labelled resin microspheres) and TheraSphere
(90Y glass microspheres) that were approved in the
early 2000s.
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2. Patient selection
SIRT with 90Y-resin microspheres is indicated for the
management of liver-dominant or liver-only primary or
secondary liver tumour(s) in patients who have a life
expectancy of at least 3 months (without infections
and no evidence of pulmonary insufﬁciency) and no
signiﬁcant hepatic functional deﬁcit.
For each patient, the appropriateness of SIRT is also
governed by a number of well-established and accepted
parameters for liver reserve and vascular access.
Liver function must be adequate, without ascites, with
normal synthetic liver function (e.g., albumin >3 g/dL),
and normal total bilirubin of less than 2.0mg/dL
(34mmol/L). 10 A small number of patients are found
to be unsuitable for treatment due to the presence
of either aberrant vessels that prevent the isolation
of the liver arterial tree from gastric and small-bowel
branches or arteriovenous ﬁstulae in tumours that allow
for more than 20% of the microspheres to pass through
the liver capillary bed to the lungs. Understanding
these exclusion criteria (as outlined by Goin) is key to
preventing avoidable complications with SIRT. 11
3. Multidisciplinary teams and the continuum of
care
Ideally SIRT should be undertaken at centres that employ
a multidisciplinary approach to planning, delivering and
reviewing cancer treatment, or upon referral from a
multidisciplinary team familiar with the procedure. In
particular, multidisciplinary team members should be
consulted with regard to the likely interactions between
SIRT and any prior, concurrent or planned biological,
chemotherapeutic, locoregional ablative, surgical or
external beam radiation therapies. A detailed clinical
history, blood tests (full blood count, serum renal
and liver function tests) as well as evidence of liver-
dominant disease based on contrast-enhanced positron
emission tomography (PET), computed tomography (CT)
or magnetic resonance imaging (MRI) are key to
informing the decision to treat. 12,13
SIRT is one element in the continuum of care. It is often
given during a treatment hiatus or following disease
progression with chemotherapy.
4. Treatment work-up
Treatment work-up includes a thorough angiographic
evaluation in order to detect extrahepatic vessels that
irrigate liver tumors and to detect, and eventually
occlude, aberrant vessels arising from hepatic arter-
ies that may feed the gastrointestinal tract (mainly
gastroduodenal artery and right gastric artery). During
this arteriography, with the tip of the catheter in
the same position where 90Y-resin microspheres will
be delivered, technetium-99m labeled macroaggregated
albumin (99mTc-MAA) is injected as a tracer, to measure
the hepatopulmonary shunt. 12,13 Planar or SPECT/CT
gamma-camera images are then used to detect any
misplacement of 99mTc-MAA in the gastrointestinal tract
and to estimate the dose of radiation to tumour and
non-tumoral tissue. 12,13
5. Treatment
Eligible patients are then invited back for the treatment
procedure. Immediately prior to the administration of
90Y-resin microspheres, an angiogram is conducted to
conﬁrm that all aberrant vessels are occluded. The
calculated implanted activity may be adjusted if there
are concerns over the extent of pre-treatment and/or
potential subsequent toxicity. 14 The microspheres are
then administered as a single or sequential lobar
application immediately followed by a Bremsstrahlung
scan to conﬁrm the correct targeted deposition of the
microspheres. 12,13 Patients are then closely monitored for
2 to 4 days after the procedure and post-embolisation
syndrome is managed, as necessary.
6. Summary
In summary, the key to successful treatment with SIRT
is appropriate selection of patients with a controllable
and identiﬁable tumour load and sufﬁcient hepatic
functional reserve. SIRT is one element in the continuum
of care for patients managed by a multidisciplinary team.
Diligent pretreatment work-up is essential with close
post-treatment follow-up to manage complications and
to prepare for subsequent treatment.
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